The global Biobanking Market is projected to grow from USD 7.65 billion in 2025 to USD 11.82 billion by 2030, registering a CAGR of 9.1% during the forecast period. Market expansion is being driven by the increasing focus on precision medicine, a rapidly growing cell and gene therapy pipeline, and advancements in automated sample handling and storage technologies.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=594
Market Dynamics: Precision Medicine and Automation Reshape Biobanking
Biobanking is becoming a critical backbone of modern healthcare and life sciences research. The growing demand for personalized therapies and biologics is significantly increasing the need for high-quality biological sample storage and management.
End-to-end automation is transforming biobank operations—improving efficiency, reducing human error, and ensuring consistent sample integrity. At the same time, sustainability initiatives and green-lab solutions are emerging as key opportunities for innovation. However, long-term funding stability, particularly for public biobanks, remains a challenge for market stakeholders.
Product Insights: Equipment Segment Leads with Critical Storage Infrastructure
By product, the equipment segment accounted for the largest share of the biobanking market in 2024. Core infrastructure such as freezers, refrigerators, and cryogenic storage systems plays a vital role in preserving biological samples including blood, tissues, and DNA.
Ultra-low temperature freezers and cryogenic systems are especially critical for maintaining the viability of sensitive materials such as stem cells, cell lines, and nucleic acids over extended periods—making them indispensable in research, diagnostics, and therapeutic development workflows.
End-User Trends: Pharma, Biotech & CROs to Drive Fastest Growth
The pharmaceutical & biotechnology companies and contract research organizations (CROs) segment is expected to register the highest growth rate during the forecast period.
This growth is fueled by increasing demand for biologics, biosimilars, and advanced therapies such as cell and gene therapies. These organizations rely heavily on biobanking services for clinical sample management, drug development, and large-scale research—driving adoption of advanced storage and data management solutions.
Regional Outlook: Asia Pacific Emerges as High-Growth Market
The Asia Pacific region is projected to register the highest CAGR during the forecast period. Countries such as China, India, and Japan are rapidly expanding their research infrastructure and healthcare capabilities.
Biobanks in the region are becoming essential for supporting drug discovery, clinical trials, and population health studies. Additionally, rising chronic disease prevalence and aging populations are increasing demand for comprehensive biobanking solutions to enable future healthcare innovations.
Sepak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=594
Competitive Landscape: Innovation and Global Expansion Intensify Competition
The biobanking market is characterized by strong competition and continuous innovation, with leading players focusing on automation, advanced storage technologies, and integrated solutions. Key companies include: The key players in the biobanking market include Thermo Fisher Scientific Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (BD) (US), Qiagen (Germany), Merck KGaA (Germany), Labcorp (US), Eurofins Scientific (Luxembourg), and Cryoport (US), among other players.
These companies are investing in scalable, automated, and sustainable biobanking solutions to meet the growing global demand for high-quality biological sample management.
Strategic Outlook: Biobanking at the Core of Next-Generation Healthcare
As life sciences shift toward precision medicine, regenerative therapies, and data-driven research, biobanking is becoming increasingly central to innovation.
Future growth will be shaped by advancements in automation, integration with digital platforms, and sustainable lab practices. Organizations that can deliver scalable, compliant, and high-integrity biobanking solutions will be well-positioned to capitalize on this expanding market.
